cold (Herbion syrups), a preparation promising improved memory and concentration (Bilobil), and an analgesic (Nalgesin S). Animal health products Krka’s animal health products include general anti-infectives, antiparasitics and insecticides, products for the alimentary tract and metabolism, and antiseptics and disinfectants. Health-resort and tourism services Krka’s line of business is supplemented by health-resort and tourist services of the subsidiary, the Terme Krka Group. It unites the business units of the spa complexes and hotels Terme Dolenjske Toplice, Terme Šmarješke Toplice, the coastal centre Talaso Strunjan, Hoteli Otočec with the only hotel in a castle in Slovenia, and the business Hotel Krka. Terme Krka’s basic line of business is the medical rehabilitation after cardiovascular and respiratory system diseases, as well as mobility problems. Markets and business network Krka is an international company, selling more than 93% of its products in more than 70 countries worldwide. Subsidiaries and representative offices are present in the most important markets, while its production capacity is also located in Russia, Poland, Croatia and Germany. Region East Europe is Krka Group’s largest sales region, representing 30.7% of total sales. It is followed by Region Central Europe with 24% of total sales and Region West Europe with 22.6% of total sales and Overseas Markets with 3.1% of total sales. In addition, Krka also sells its products in Africa, the Arabian Peninsula and the Far East. Krka achieved 12,7% of total sales in Region South-East Europe. Krka sells 6.9% of its products and services in Slovenia, being the leading pharmaceutical producer there. Krka’s markets extend from Lisbon to Vladivostok. Krka has 25 subsidiaries and 20 representative offices abroad, which employ 52.6% of all workers. Research and development In 2017 Krka acquired first marketing authorizations for 23 new products in 46 pharmaceutical dosage forms and strengths. In several countries, Krka also obtained 555 new marketing authorizations for various products. History Krka’s pharmaceutical laboratory was founded in 1954; two years later it was transformed into a production plant. Krka registered its first pharmaceuticals on the domestic market and made inroads into foreign markets in the 1960s. During this time, Krka supplemented its offer with licensed products, obtaining its first FDA registration for antibiotics production. In the early 1980s, Krka focused on the development of own generic products with added value. In the 1980s, Krka started to develop its marketing network and strengthened its position on European markets. By placing its shares on